Rachael Murphy, MD
Internal Medicine · Covington, LANPI 1528039781
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.1% of the total across 700 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 700 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Modernatx, Inc.$1K
- Novo Nordisk$1K
- Lilly USA, LLC$938
- AstraZeneca$758
- Sunovion Pharmaceuticals Inc.$745
- plus $7K from 52 others
Across 35 payments — averaging $10,170 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$204K
- Modernatx, Inc.$93K
- Swing Therapeutics, Inc.$30K
- BD$16K
- AstraZeneca$14K
What the payments were for
- Travel & lodging$1,1358%
- Food & beverage$12,74191%
- Education$1121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,988 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 75 | $96,846 |
| FarxigaDapagliflozin Propanediol | 44 | $42,750 |
| OzempicSemaglutide | 36 | $42,711 |
| CreonLipase/Protease/Amylase | 25 | $30,240 |
| ProliaDenosumab | 11 | $19,368 |
| EliquisApixaban | 20 | $19,108 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $16,576 |
| XareltoRivaroxaban | 14 | $16,406 |
| GlyxambiEmpagliflozin/Linagliptin | 16 | $14,233 |
| MyrbetriqMirabegron | 15 | $13,598 |
| TrulicityDulaglutide | 12 | $12,333 |
| LinzessLinaclotide | 15 | $9,447 |
| SynthroidLevothyroxine Sodium | 105 | $8,953 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $8,265 |
| UnithroidLevothyroxine Sodium | 59 | $6,868 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $938 | $109,17987 claims |
| AbbVieCreon, Linzess, Synthroid, Armour Thyroid | $1,939 | $51,905180 claims |
| AstraZenecaFarxiga | $758 | $42,75044 claims |
| Novo NordiskOzempic | $1,225 | $42,71136 claims |
| AmgenProlia | $203 | $19,36811 claims |
| PfizerEliquis | $673 | $19,10820 claims |
| GSKTrelegy Ellipta | $734 | $16,57624 claims |
| Johnson & JohnsonXarelto | $100 | $16,40614 claims |
| Boehringer IngelheimGlyxambi | $309 | $14,23316 claims |
| Astellas Pharma US IncMyrbetriq | $343 | $13,59815 claims |
| Amneal Pharmaceuticals LLCUnithroid | $260 | $6,86859 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $15 | $95517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Covington
- Bruce SamuelsCovington$200K
- David TranCovington$32K
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
- Amanda FontenotMarrero$142K
- John SchwabBaton Rouge$122K
- Daniel EnglertNew Orleans$74K
- Everett BrownGretna$71K
- Rajan KhannaShreveport$54K
- Samuel StaggEunice$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.